Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

out Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, endocrinology, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze. Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of different enzymes in its portfolio that target significant areas of unmet medical need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, (i) statements relating to the benefits of a faster acting insulin product and (ii) conclusions and implications drawn from clinical and pre-clinical trial data for PEGPH20 and Chemophase) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward- looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in fo
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... ... joint disease. , Equine cervical facet joint problems can be caused by ... and can cause impingement of nerve roots or of the spinal cord itself. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the ... the opportunities for advanced analytics utilizing data lakes in the healthcare industry. , As ... seen an explosion of data over the last few years as more entities become ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... diseases has been discovered by researchers at the Keck Graduate Institute and its ... untreatable diseases. , The findings were published online on August 27 by Scientific ...
(Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... of Directors as a Non-Executive Director. Sara will also be ... the Shire Board. Both appointments will be effective as of ... President and Chief Executive Officer of Dun & Bradstreet, Inc. ... D&B, she helped drive the transformation of the company from ...
Breaking Biology Technology:VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4Shire Appoints Sara Mathew to Board of Directors 2
... March 6, the Air Force Office of Scientific Research ... Mirkin from Northwestern University. Professor Mirkin is a ... for his development of nanoparticle-based biodetection schemes, the invention ... his contributions to supramolecular chemistry, nanoelectronics, and nanooptics. He ...
... WOODLANDS, Texas, March 20, 2012   Lexicon Pharmaceuticals, ... that the U.S. Food and Drug Administration (FDA) has ... telotristat etiprate (LX1032) for the treatment of carcinoid ... neuroendocrine tumors that usually originate from the gastrointestinal tract ...
... March 20, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... Inc. has received approval from the United States Food ... (ANDA) for Ibandronate 150mg tablets, the generic equivalent to ... product in the second quarter. BONIVA® 150mg tablets had ...
Cached Biology Technology:Air Force Office of Scientific Research hosts nanotechnology pioneer 2Air Force Office of Scientific Research hosts nanotechnology pioneer 3Air Force Office of Scientific Research hosts nanotechnology pioneer 4FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 2FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 3FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 4Watson's Generic BONIVA® 150mg Receives FDA Approval 2
(Date:8/31/2015)... Canada , August 31, 2015 ... of biometrics technology in government digitization projects to drive ... to a recently published TechSci Research report, " India Biometrics ... India is projected to grow at a ... the market is anticipated on account of extensive use of ...
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... triggered changes in the type of sperm a male produces, ... The study, published in the Proceedings of the National ... for reproduction influences the sperm of many species of African ... strict monogamy to species where females mate with many males ...
... (Jan. 21, 2009) Finding cures for hearing loss, ... identify people at risk for tuberculosis are goals of ... L.E. Simmons Family Foundation Collaborative Research Fund. The fund, ... diagnose and treat diseases, supports collaboration among researchers at ...
... This month, the City of Newark, Delaware became the ... car to store and provide power for the local ... electricity alone, is specifically designed to store energy and ... the concept, called Vehicle-to-Grid (V2G). With the City of ...
Cached Biology News:The more promiscuous the female, the speedier the sperm 2Texas Medical Center researchers win collaborative grants 2Texas Medical Center researchers win collaborative grants 3Texas Medical Center researchers win collaborative grants 4City of Newark first in nation using cars to power grid 2
... for rapid, convenient, and efficient native protein ... utilizes a spin column to make handling ... of proteins which were electro-eluted in their ... exchangers, offering high binding capacity fo all ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... suspension array system, 100-240 V, uses xMAP ... to 100 proteins and peptides in one ... of up to 100 color-coded bead sets, ... a unique reactant (enzyme substrates, receptors, antigens, ...
Biology Products: